An Integrated Population Pharmacokinetic Model Versus Individual Models of Depatuxizumab Mafodotin, an Anti-EGFR Antibody Drug Conjugate, in Patients With Solid Tumors Likely to Overexpress EGFR

2019 ◽  
Author(s):  
Rajendar K. Mittapalli ◽  
Sven Stodtmann ◽  
Anna Friedel ◽  
Rajeev M. Menon ◽  
Earle Bain ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Population Pharmacokinetic Model ◽  
Pharmacokinetic Model ◽  
Population Pharmacokinetic ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Model Versus ◽  
Antibody Drug ◽  
Egfr Antibody

Abstract A088: Novel anti-EGFR antibody-drug conjugate AVID100: A phase 2a trial in patients with EGFR-overexpressing advanced solid tumors

2019 ◽  
Author(s):  
Jason Melear ◽  
Nehal Lakhani ◽  
Joyce A O'Shaughnessy ◽  
Sharon T Wilks ◽  
Saad Khan ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug ◽  
Egfr Antibody

28LBA A phase 1 study of PF-06647020, an antibody-drug conjugate targeting PTK7, in patients with advanced solid tumors

2015 ◽  
Vol 51 ◽  
pp. S724 ◽  
Author(s):  
A.W. Tolcher ◽  
E. Calvo ◽  
M.L. Maitland ◽  
B. Gibson ◽  
D. Xuan ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Phase 1 ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Phase 1 Study ◽  
Drug Conjugate ◽  
Antibody Drug

Abstract 52: Mechanistic and benchmarking studies of ADCT-502, a pyrrolobenzodiazepine (PBD) dimer-containing antibody-drug conjugate (ADC) targeting HER2-expressing solid tumors

2017 ◽  
Author(s):  
Francesca Zammarchi ◽  
Halla W. Reinert ◽  
Narinder Janghra ◽  
Simon Corbett ◽  
Maria Mellinas-Gomez ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document